Generic Name: ceritinib

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Targeted Therapy Medications

Company: Novartis

Approval Status: Approved

Generic Version Available: No

Experimental Code: N/A

Drug Indication

Zykadia is a kinase inhibitor approved for the treatment of ALK-positive metastatic non-small-cell lung cancer (NSCLC).

General Info

Zykadia interferes with anaplastic lymphoma kinase (ALK) and other receptor tyrosine kinases that play a role in cancer cell growth.

The ASCEND clinical trials showed that Zykadia improved response rates and delayed disease progression compared with chemotherapy in people with previously untreated metastatic ALK-positive NSCLC and in those who did not respond to the older ALK inhibitor Xalkori (crizotinib). Zykadia was approved in 2014.


Dosing Info:

Zykadia is taken tablet or capsule once daily with food.

Side Effects

Common adverse events include diarrhea, nausea, abdominal pain, vomiting and fatigue. More serious side effects may include severe gastrointestinal problems, liver toxicity, lung inflammation, heart rhythm abnormalities, pancreas inflammation and high blood glucose. Zykadia can cause fetal harm if used during pregnancy.

For More Info:

Patient Assistance Program Info:

Last Reviewed: August 22, 2019